ClinicalTrials.gg
CompletedNCT00673205CapriUpdated Dec 10, 2010

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

A Phase 3 interventional study of Bicalutamide and Placebo in Non-Metastatic Prostate Cancer, sponsored by AstraZeneca. Completed at 130 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,588
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Enrollment
3rd of 54
3,588 · median 53
Started
1995
with 2 others
Phase 3
21 of 55
1 open now
Registered
26th of 55
by date
Lead sponsor
8 of 55
AstraZeneca

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 3rd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 1995, is one of 21 in phase 3, and was the 26th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

03

Conditions studied

  • Non-Metastatic Prostate Cancer

Browse trials for

Keywords

  • androgen antagonists
  • prostate neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of non- cancer of the prostate gland
  • Patient to be 18 years and above

Exclusion criteria

Exclusion Criteria:

  • Previous systemic therapy for prostate cancer
  • Previous history of another form of cancer (not prostate) within 5 years of study start.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3,588 participants (actual)

Study arms

  • Placebo comparator
    A

    Drug: Placebo

  • Active comparator
    B

    Drug: Bicalutamide

Interventions

  • 150mg p.o. daily

    Also known as: Casodex

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Time to clinical progression

    Time frame: Throughout study period

  2. Tolerability in terms of adverse events and laboratory parameters

    Time frame: Throughout study period

Secondary outcomes

  1. Survival

    Time frame: Throughout study period

  2. Time to treatment failure

    Time frame: Throughout study period

  3. Prostate-specific antigen

    Time frame: Initial study period up to 2005 amended protocol

07

Study locations

130 sites
  • Research Site
    Wooloongabba, Queensland, Australia
  • Research Site
    East Melbourne, Victoria, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Linz, Austria
  • Research Site
    Mistelbach, Austria
  • Research Site
    Oberwart, Austria
  • Research Site
    St. Polten, Austria
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Brugge, Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Kortrijk, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Mons, Belgium
  • Research Site
    Oostende, Belgium
  • Research Site
    Seraing, Belgium
  • Research Site
    Brno, Czech Republic
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Praha 4, Czech Republic
  • Research Site
    Praha 5, Czech Republic
  • Research Site
    Berlin, Germany
  • Research Site
    Bonn, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Jena, Germany
  • Research Site
    Lubeck, Germany
  • Research Site
    Ludenscheid, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Regensburg, Germany
  • Research Site
    Sigmaringen, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Dublin 4, Ireland
  • Research Site
    Dublin 7, Ireland
  • Research Site
    Haifa, Israel
  • Research Site
    Petach Tikva, Israel
  • Research Site
    Tel-aviv, Israel
  • Research Site
    Tel-hashomer, Israel
  • Research Site
    Bari, BA, Italy
  • Research Site
    Bergamo, BG, Italy
  • Research Site
    Belluno, BL, Italy
  • Research Site
    Bologna, BO, Italy
  • Research Site
    Brescia, BS, Italy
  • Research Site
    Como, CO, Italy
  • Research Site
    Cesena, FO, Italy
  • Research Site
    Anagni, FR, Italy
  • Research Site
    Carpi, MO, Italy
  • Research Site
    Fidenza, PR, Italy
  • Research Site
    Siena, SI, Italy
  • Research Site
    Torino, TO, Italy
  • Research Site
    Treviso, TV, Italy
  • Research Site
    Udine, UD, Italy
  • Research Site
    Varese, VA, Italy
  • Research Site
    Dolo, VE, Italy
  • Research Site
    Portogruaro, VE, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Mexico, Mexico
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Breda, Netherlands
  • Research Site
    Capelle A/d Ijssel, Netherlands
  • Research Site
    Eindhoven, Netherlands
  • Research Site
    Enschede, Netherlands
  • Research Site
    Gouda, Netherlands
  • Research Site
    Heerlen, Netherlands
  • Research Site
    Maastricht, Netherlands
  • Research Site
    Nijmegen, Netherlands
  • Research Site
    Roosendaal, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Spijkenisse, Netherlands
  • Research Site
    Utrecht, Netherlands
  • Research Site
    Warszawa, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Almada, Portugal
  • Research Site
    Coimbra, Portugal
  • Research Site
    Lisboa, Portugal
  • Research Site
    Porto, Portugal
  • Research Site
    Vila Nova de Gaia, Portugal
  • Research Site
    Somerset West, Cape Town, South Africa
  • Research Site
    Bloemfontein, South Africa
  • Research Site
    Cape Town, South Africa
  • Research Site
    Durban, South Africa
  • Research Site
    George, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Pietermarizberg, South Africa
  • Research Site
    Pretoria, South Africa
  • Research Site
    Granada, Andalucia, Spain
  • Research Site
    Malaga, Andalucia, Spain
  • Research Site
    Sevilla, Andalucia, Spain
  • Research Site
    Oviedo, Asturias, Spain
  • Research Site
    Guadalajara, Castilla La Mancha, Spain
  • Research Site
    Salamanca, Castilla Leon, Spain
  • Research Site
    Badalona(barcelona), Cataluna, Spain
  • Research Site
    Barcelona, Cataluna, Spain
  • Research Site
    Hospitalet de Llobregat(barcel, Cataluna, Spain
  • Research Site
    Alcala de Henares, Comunidad de Madrid, Spain
  • Research Site
    Getafe, Comunidad de Madrid, Spain

Showing the first 100 of 130 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x. PubMed 22129214 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1995, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 7, 2008
Start
Sep 1995
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Dec 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00673205
Lead sponsor
AstraZeneca
First posted
May 7, 2008
Start date
Sep 1995
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Dec 10, 2010

Study contacts

Manfred P Wirth, Professor
principal investigator · Technical University of Dresden, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion